Showcasing Southern California's innovation, one startup at a time. Every funded and bootstrapped company, from seed round to first dollar of revenue, tracked as it happens.
Includes SEC Form D filings from the last 3 years, plus all-time totals for companies sourced from YC and news coverage.

The region's largest single cluster by company count — AI and machine learning threaded through nearly every other industry here, from defense to biotech to entertainment.

Home to SpaceX, Northrop Grumman, and a new wave of hypersonics and space-infrastructure startups.

Hollywood's production infrastructure, live events, and a growing games and creator-tools scene.

Qualcomm and Broadcom anchor a chip-design cluster spanning the region.

A deep biotech research base and a growing bench of medical device and diagnostics startups.

Business software and services sold to other companies. The largest single category of startup across Southern California, spanning sales tools, vertical operating systems, and everything in between.

Manufacturing, hardware, and physical-world operations. Overlaps heavily with the region's decades-old aerospace and defense manufacturing base, now extending into robotics and automated production.

Products and apps built directly for individual consumers, drawing on Southern California's media and entertainment base.

Health tech, medical devices, and healthcare services, backed by a decades-old biotech research base and a deep bench of clinical and diagnostics startups.

Financial technology: payments, banking, investing, and financial infrastructure.

Education technology and learning platforms built across Southern California.

Property technology, construction tech, and real estate services.
LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.
Blending a Japanese style whisky that harmonizes Japanese nature and artisanship
Co-founded in 2016 by Matthew Geller, Jared Kapela, and Patrick Lennon; the company has been backed by Techstars.
Convexa invests in early-stage/growth technology companies that promise to deliver high growth and exceptional returns.

This San Diego ophthalmic biotech raised $10 million in Series A funding in 2018 from Brandon Capital's Medical Research Commercialisation Fund, and secured another $3.3 million in December 2024 to advance a Phase 2b trial for a pink-eye (acute infectious conjunctivitis) treatment.